Literature DB >> 18393054

Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.

David A Fiellin1, Brent A Moore, Lynn E Sullivan, William C Becker, Michael V Pantalon, Marek C Chawarski, Declan T Barry, Patrick G O'Connor, Richard S Schottenfeld.   

Abstract

To examine long-term outcomes with primary care office-based buprenorphine/naloxone treatment, we followed 53 opioid-dependent patients who had already demonstrated six months of documented clinical stability for 2-5 years. Primary outcomes were retention, illicit drug use, dose, satisfaction, serum transaminases, and adverse events. Thirty-eight percent of enrolled subjects were retained for two years. Ninety-one percent of urine samples had no evidence of opioid use, and patient satisfaction was high. Serum transaminases remained stable from baseline. No serious adverse events related to treatment occurred. We conclude that select opioid-dependent patients exhibit moderate levels of retention in primary care office-based treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393054     DOI: 10.1080/10550490701860971

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  61 in total

Review 1.  Update in addiction medicine for the generalist.

Authors:  Adam J Gordon; Hillary V Kunins; Darius A Rastegar; Jeanette M Tetrault; Alexander Y Walley
Journal:  J Gen Intern Med       Date:  2010-08-10       Impact factor: 5.128

2.  Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization.

Authors:  Phoebe A Cushman; Jane M Liebschutz; Bradley J Anderson; Merredith R Moreau; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2016-06-11

3.  Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.

Authors:  Gail D'Onofrio; Marek C Chawarski; Patrick G O'Connor; Michael V Pantalon; Susan H Busch; Patricia H Owens; Kathryn Hawk; Steven L Bernstein; David A Fiellin
Journal:  J Gen Intern Med       Date:  2017-02-13       Impact factor: 5.128

4.  Interpretation and integration of the federal substance use privacy protection rule in integrated health systems: A qualitative analysis.

Authors:  Aimee N C Campbell; Dennis McCarty; Traci Rieckmann; Jennifer McNeely; John Rotrosen; Li-Tzy Wu; Gavin Bart
Journal:  J Subst Abuse Treat       Date:  2018-11-19

5.  Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.

Authors:  Zoe M Weinstein; Gabriela Gryczynski; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong W Kim; Colleen Labelle; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2018-06-19       Impact factor: 4.492

6.  Emerging adult age status predicts poor buprenorphine treatment retention.

Authors:  Zev Schuman-Olivier; Roger D Weiss; Bettina B Hoeppner; Jacob Borodovsky; Mark J Albanese
Journal:  J Subst Abuse Treat       Date:  2014-05-20

7.  Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients.

Authors:  Emlyn S Jones; Brent A Moore; Jody L Sindelar; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2008-09-19       Impact factor: 4.492

Review 8.  Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.

Authors:  E Jennifer Edelman; David A Fiellin
Journal:  Am J Prev Med       Date:  2013-01       Impact factor: 5.043

Review 9.  Narrative review: buprenorphine for opioid-dependent patients in office practice.

Authors:  Lynn E Sullivan; David A Fiellin
Journal:  Ann Intern Med       Date:  2008-05-06       Impact factor: 25.391

10.  Characteristics of inmates witnessing overdose events in prison: implications for prevention in the correctional setting.

Authors:  Carmen E Albizu-García; Adriana Hernández-Viver; Jacqueline Feal; José F Rodríguez-Orengo
Journal:  Harm Reduct J       Date:  2009-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.